• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • BMS’ Opdivo/Yervoy combo cleared for kidney cancer pharmatimes
    July 16, 2018
    US regulators have approved a combination of Bristol-Myers Squibb’s immunotherapy drugs Opdivo and Yervoy as a first-line treatment for patients with advanced renal cell carcinoma.
  • BMS’ Opdivo/Yervoy combo cleared for kidney cancer pharmatimes
    July 16, 2018
    US regulators have approved a combination of Bristol-Myers Squibb’s immunotherapy drugs Opdivo and Yervoy as a first-line treatment for patients with advanced renal cell carcinoma.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Event Data Sharing Notice
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service